P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies
Grazia Gargano(Istituto Tumori Bari), Sabino Ciavarella(Istituto Tumori Bari), Maria Carmela Vegliante(Aristotle University of Thessaloniki), Doriana Gramegna(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Angela Maria Quinto(Platinum Group Coatings (United States)), Paolo Mondelli(Istituto Tumori Bari), Flavia Esposito(Istituto Tumori Bari), Carolina Terragna(Fondazione Gimema Onlus), Vincenza Solli, Attilio Guarini(Istituto Tumori Bari), Michèle Cavo(Unknown), Giuseppina Opinto(Istituto Tumori Bari), Susanna Anita Pappagallo(Istituto Tumori Bari), Orazio Palumbo(Casa Sollievo della Sofferenza), Bernardo Rossini(Istituto Tumori Bari), Nicoletta Del Buono
Cited by 0
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719